Kodiak Sciences Inc.
2631 Hanover Street
Palo Alto
CA
94304
United States
Tel: 650281-0810
74 articles with Kodiak Sciences Inc.
-
Kodiak Sciences to Host R&D Day on October 14 in San Francisco to Highlight Recent Clinical Progress and Development Planning for KSI-301
10/11/2019
Kodiak Sciences Inc. will host an R&D Day in San Francisco to highlight significant progress in the development of its lead therapeutic candidate KSI-301.
-
Kodiak Sciences Treats First Patients in DAZZLE Pivotal Study of KSI-301 in Wet Age-Related Macular Degeneration
10/10/2019
KSI-301, in patients with treatment-naïve wet age-related macular degeneration
-
Kodiak Sciences Announces Upcoming Presentation of Durability Data from Clinical Development Program of KSI-301 in Wet AMD, DME, and RVO at American Academy of Ophthalmology 2019 Annual Meeting
10/7/2019
Kodiak Sciences Inc. announced that Charles C. Wykoff, M.D., Ph.D., will present first-time results at the Annual Meeting of the American Academy of Ophthalmology (AAO) to be held in San Francisco, California.
-
Kodiak Sciences Announces Emerging Durability Data from Ongoing Phase 1b Study of KSI-301 in Wet AMD Patients at The Retina Society Annual Meeting
9/15/2019
Late-breaking results support Kodiak's objective of every three-, four-, and five-month long-interval dosing of KSI-301 in patients with wet AMD
-
Kodiak Sciences to Release Durability Data from Clinical Development Program of KSI-301 for wet AMD at The Retina Society Annual Meeting
9/12/2019
Late-Breaking Results Include First Durability Data from Phase 1b Study of KSI-301 in Treatment-Naïve Patients with Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusion [12-September-2019] PALO ALTO, Calif. , Sept. 12, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel therapeut
-
Kodiak Sciences to Present at the Morgan Stanley Global Healthcare Conference
9/6/2019
Kodiak Sciences Inc. announced that management will participate in the Morgan Stanley Global Healthcare Conference in New York, NY on Monday, September 9 at 4:50 p.m. Eastern Time.
-
Kodiak Sciences Announces Upcoming Presentations at EURETINA Meeting
9/4/2019
Kodiak Sciences Inc. announced that presentations on its research will be made at EURETINA 2019 Congress being held from September 5 – 8 in Paris, France.
-
Kodiak Sciences Announces Second Quarter 2019 Financial Results and Recent Business Highlights
8/14/2019
Kodiak Sciences Inc., a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, reported business highlights and financial results for the second quarter ended June 30, 2019.
-
Kodiak Sciences to Present at Wedbush PacGrow Healthcare Conference
8/8/2019
Kodiak Sciences Inc. announced that management will present at the Wedbush PacGrow Healthcare Conference in New York, NY on Wednesday, August 14 at 10:20 a.m. Eastern Time.
-
Kodiak Sciences Announces Positive Interim Data from Ongoing Phase 1b Clinical Study of KSI-301, a Novel Anti-VEGF Antibody Biopolymer Conjugate for Treatment of Wet AMD, Diabetic Eye Disease, and Retinal Vein Occlusion, at the ASR
7/27/2019
Kodiak Sciences Inc. announced positive interim results from the ongoing Phase 1b study of KSI-301, its investigational intravitreal anti-VEGF antibody biopolymer conjugate in patients with anti-VEGF treatment-naïve neovascular age-related macular degeneration, diabetic macular edema, and macular edema due to retinal vein occlusion.
-
Kodiak Sciences Announces Upcoming Presentation at American Society of Retina Specialists (ASRS) 2019 Annual Meeting
7/24/2019
Initial Phase 1b data for KSI-301 in Wet AMD, DME, and RVO to be presented
-
Kodiak Sciences to Present at the Jefferies 2019 Healthcare Conference
5/31/2019
Kodiak Sciences Inc. announced that management will present at the Jefferies 2019 Healthcare Conference in New York, NY on Thursday, June 6 at 2:00 p.m. Eastern Time.
-
Kodiak Sciences Announces First Quarter 2019 Financial Results and Recent Business Highlights
5/15/2019
Kodiak Sciences Inc. reported business highlights and financial results for the first quarter ended March 31, 2019.
-
Kodiak Sciences to Present at the Bank of America Merrill Lynch Health Care Conference 2019
5/9/2019
Kodiak Sciences Inc. announced that management will present at the Bank of America Merrill Lynch Health Care Conference in Las Vegas, NV on Wednesday, May 15, at 5:00 p.m. Pacific Time.
-
Kodiak Sciences Announces Presentations at ARVO 2019 Annual Meeting
4/25/2019
Kodiak Sciences Inc. announced that presentations on its research will be made at the Association for Research in Vision and Ophthalmology 2019 Annual Meeting, being held from April 28 – May 2 in Vancouver, Canada.
-
Kodiak Sciences Announces Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights
3/28/2019
Kodiak Sciences Inc., a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, reported business highlights and financial results for the fourth quarter and full year ended December 31, 2018.
-
The San Francisco Business Times recently looked at top alumni from Bay Area incubators. Some of those companies are now brand-name companies like Uber and Reddit. Here’s a look at the biotech companies on their list.
-
Kodiak Sciences Announces Upcoming Presentation of KSI-301 12-Week Phase 1a Study Data at Angiogenesis, Exudation, and Degeneration 2019 Meeting
2/8/2019
Kodiak Sciences Inc. announced that a presentation on its investigational therapy KSI-301 will be made at the Angiogenesis, Exudation, and Degeneration 2019 meeting being held on February 9, 2019 in Miami, FL.
-
The Nasdaq indicated that there was a record amount of biotech initial public offerings this year, including some individual record-breakers—Moderna, Allogene Therapeutics and Rubius Therapeutics. The total for the year is around $8.2 billion raised, breaking 2014’s record of $6.5 billion.
-
Kodiak Sciences Added to Russell 2000®, 3000® and Microcap® Indexes
12/24/2018
Kodiak Sciences Inc. today announced that it has been added to the Russell 2000®, 3000® and Microcap® Indexes, effective as of the open of the U.S. markets on Monday, December 24, 2018.